Enliven Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 5 →InsidersNo open-market buys. 10 insiders sold $64.7M, 46 of 53 sales on a 10b5-1 plan.→HoldersFMR 13.7%Orbimed 9.3%Polar Capital 8.8%→PeersClosest companies: PRLD, KYMR, RVMD→
From the filings
Figures
- Net income
- −$105.9Mlast 12 months
- Operating cash flow
- −$65.5Mlast 12 months
- Cash and equivalents
- $135.5Mat the last balance sheet
- Shares outstanding
- 73.3M shareson issue